As of April 30, 2025, there are 82 publicly listed companies in China engaged in the in vitro diagnostics (IVD) industry. Among them, 61 companies focus primarily on IVD, while 21 have IVD as part of their broader business portfolios.

In 2024, China’s IVD market size is expected to be less than RMB 120 billion, remaining flat compared to 2023. Domestic brands account for approximately 50% of the market.

Freenome announced today that it has closed a $160 million Series B financing round, which it will use to further develop its early cancer detection blood test.

Thermo Fisher Scientific, the world leader in serving science, recently announced that it will be investing more than $50m (£39.8m) in its global bioproduction capabilities to provide additional capacity for manufacturing single-use bioproc

A new public-private consortium is collaborating on a project whose chief objective is an FDA-qualified composite biomarker for diagnosing nonalcoholic steatohepatitis (NASH). If all goes as planned, physicians and researchers will for the f

Biodesix isn’t looking to just be another company with lung cancer detection tests. It wants to be the lung cancer detection company. And with its most recent acquisition, the Boulder, CO-just might achieve that goal.

Biological Dynamics is fighting to take its diagnostic platform to the next level. And the San Diego-based company said it recently received a grant from the Bill & Melinda Gates Foundation, to help it in its mission.

ArcherDX is bringing it up a notch through a new collaboration with Ayala Pharmaceuticals, a clinical stage precision oncology company.

At the Massachusetts institute of technology researchers have invented a sensor that can speed up the process of diagnosis of sepsis recently held in Berlin, Germany's engineering conference, medicine and biology, researchers have published

Thermo Fisher Scientific said today that it has acquired HighChem, a developer of mass spectrometry software based in Slovakia.

The global blood gas analyzers market was valued at USD 594.6 million in 2017 and is projected to grow at a CAGR of 5.5% over the forecast period (2018 – 2026) to surpass USD 940 million by 2026. The market growth is expected to be driven

The global blood coagulation analyzer market is projected to grow at a substantial CAGR of 5.9% over the period 2018 to 2023, driven by its increasing scope, product types, and applications.